Among the other SBS signatures, the presence of SBS18, known to be caused by reactive oxygen species damage and associated with resistance to CART in diffuse large B-cell lymphoma [34], was associated with shorter EFS, with 4 out of 5 patients (80%) progressing after anti-CD38 MoAb combination treatment (P = 0.03 estimated using log-rank test; Fig. 2C and Supplemental Table 6). The gene discussed is CD38; the disease is diffuse large B-cell lymphoma.